close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Medical History

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Medical History

Review your patient’s information.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Loretta Nastoupil , Hematologist, Oncologist

location-icon

Houston, TX

LOCATION OF PRACTICE
Mercy Hospital
MEDICAL Specialty:

Non-hodgkin Lymphoma



NPI Number
1407048630
ABOUT

Loretta Nastoupil, MD is a hematologist and medical oncologist at Mercy Hospital. Dr. Nastoupil served as an associate professor of medicine for more than 10 years, has published an extensive list of peer-reviewed articles, and is a member of several relevant professional organizations.

Dr. Nastoupil received her medical degree from University of Texas Southwestern Medical School at Dallas.

Dr. Loretta Nastoupil profile image

Published Articles

Health Equity for Oncology Patients in Rural America: Insurmountable Challenges or Opportunity to Make a Real Difference.- 2026 Jun 4
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.- 2026 Jun 4
Breast Implant-Associated Malignancies: Current Recommendations for Workup and Management.- 2026 May 1
Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.- 2026 Jun
Assessing patient perspectives on enrollment in lymphoma clinical trials.- 2026 Apr 15
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.- 2026 Mar 7
A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.- 2026 Jan 20
Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma.- 2026 Apr
Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma.- 2026 Mar
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.- 2026 Mar 10

Clinical Trials

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

My Patient Resources

Other Specialists treating Non-Hodgkin Lymphoma in Houston, TX

See All Doctors

Dr. Adan Rios

Specialty: Oncology

My Resources
location-icon

UT Health

My Resources

Dr. Sai Pingali

Specialty: Hematology Oncology

My Resources
location-icon

Houston Methodist

My Resources

Dr. Premal Lulla

Specialty: Hematology Oncology

My Resources
location-icon

Baylor College of Medicine

My Resources

Dr. Jason Westin

Specialty: Oncology

My Resources
location-icon

MD Anderson Cancer Center

My Resources

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider